Comparison of acute phase reactant pentraksin-3 and inflammatory parameters in acute and stable pulmonary embolism

A. Çimen (istanbul, Turkey), A. Kalpaklioglu (kirikkale, Turkey)

Source: Virtual Congress 2021 – Pulmonary embolism in non-COVID-19 and COVID-19 patients
Session: Pulmonary embolism in non-COVID-19 and COVID-19 patients
Session type: E-poster
Number: 510

Congress or journal article abstract

Rating: 5
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Çimen (istanbul, Turkey), A. Kalpaklioglu (kirikkale, Turkey). Comparison of acute phase reactant pentraksin-3 and inflammatory parameters in acute and stable pulmonary embolism. 510

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
The Importance of the local expression of acute phase reactants in the COPD
Source: Annual Congress 2010 - COPD: systemic inflammation and comorbidities
Year: 2010


Can we predict the massiveness of acute pulmonary embolism in stable patients?
Source: Annual Congress 2010 - Pulmonary embolism
Year: 2010


Comparison of local and systemic thrombolytic treatment for acute massive pulmonary embolism
Source: Eur Respir J 2007; 30: Suppl. 51, 544s
Year: 2007

Comparison of computed tomography features of acute phase of cardiogenic pulmonary edema and acute lung injury
Source: Annual Congress 2011 - Acute respiratory failure
Year: 2011

Treatment of acute pulmonary embolism
Source: School Course 2014 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2014



Treatment of acute pulmonary embolism
Source: ERS Course 2020 - Pulmonary hypertension and pulmonary vascular disease
Year: 2020

Treatment of acute pulmonary embolism
Source: ERS Course 2017 - Pulmonary Hypertension and Pulmonary Vascular Disease
Year: 2017

Treatment of acute pulmonary embolism
Source: ERS Skills course - Pulmonary hypertension and pulmonary vascular disease
Year: 2018

Assessing of the liver function tests in patients with acute pulmonary embolism
Source: Eur Respir J 2005; 26: Suppl. 49, 522s
Year: 2005

Can mean platelet volume be an inflammatory marker in acute exacerbation of chronic obstructive pulmonary disease?
Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment
Year: 2009


Time course of systemic inflammatory markers during acute exacerbation of COPD
Source: Eur Respir J 2007; 30: Suppl. 51, 555s
Year: 2007

The rate of pulmonary thromboembolism in acute exacerbation of chronic obstructive pulmonary disease
Source: Eur Respir J 2005; 26: Suppl. 49, 297s
Year: 2005

How many patients recover from acute kidney injury after pulmonary embolism?
Source: Virtual Congress 2020 – Pulmonary embolism and beyond
Year: 2020


The challenge of acute exacerbation of pulmonary fibrosis
Source: International Congress 2014 – PG01 Challenges faced when diagnosing idiopathic interstitial lung disease
Year: 2014




Cardiac biomarkers and outcome in patients with acute exacerbation of chronic obstructive pulmonary disease
Source: Annual Congress 2012 - COPD exacerbation
Year: 2012


Update on acute pulmonary embolism
Source: Eur Respir Rev 2009; 18: 137-147
Year: 2009


D-dimer testing in patients with acute exacerbation of COPD and suspected pulmonary embolism
Source: International Congress 2015 – Pulmonary hypertension in lung disease
Year: 2015


Assessment of myocardial injury in low-risk acute pulmonary embolism
Source: International Congress 2019 – Pulmonary embolism: from diagnosis to prognosis and treatment
Year: 2019